United States:
Pfizer/Seagen And What May Follow
To print this article, all you need is to be registered or login on Mondaq.com.
Member Matthew Gardella was a panelist on
Scrip's M&A Podcast, where he discussed the state
of biopharma M&A, including the record pace of activity in 2023
and the implications of mega deals like the Pfizer/Seagen
merger.
SOURCE
Scrip M&A Podcast
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Corporate/Commercial Law from United States
Corporate Transparency Act Update
Shulman Rogers
With the arrival of spring and the first set of Corporate Transparency Act (CTA) filing deadlines behind us, it is a good time for an update on lessons learned from the initial filings.
Compliance Isn't The Only 'AI Washing' Risk
Bracewell
Companies are rapidly adopting artificial intelligence technologies, and both regulators and private plaintiffs have set their sights on "AI washing," where businesses tout AI capabilities that do not exist.
